Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2013

Open Access 01-12-2013 | Research

The investigation of 125I seed implantation as a salvage modality for unresectable pancreatic carcinoma

Authors: Hao Wang, Junjie Wang, Yuliang Jiang, Jinna Li, Suqing Tian, Weiqiang Ran, Dianrong Xiu, Yang Gao

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2013

Login to get access

Abstract

Background

To assess the efficacy of intraoperative ultrasound-guided implantation of 125I seeds for the treatment of unresectable pancreatic carcinoma, and analyze the associated prognostic factors.

Methods

Twenty-eight patients with pancreatic carcinoma who underwent laparotomy and were considered to have unresectable tumors were included in this study. Nine patients were pathologically diagnosed with Stage II disease, and nineteen patients with Stage III disease. Twenty-eight patients received intraoperative ultrasound-guided 125I seed implantation and received a D90 (at least 90% of the tumor volume received the reference dose) ranging from 60 to 163 Gy, with a median of 120 Gy. Seven patients received an additional 35–50 Gy external beam radiotherapy after seed implantation, and ten patients received two to ten cycles of chemotherapy. Overall survival of the patients was calculated and prognostic factors were evaluated.

Results

Of the patients, 94.1% (16/17) achieved good to medium pain relief. The tumor response rate was 78.6% (22/28), and local control was achieved in 85.7% (24/28) of patients. The 1-, 2- and 3-year survival rates were 30%, 11% and 4%, and the median survival was 10.1 months (95% CI: 9.0-10.9). Analysis using the Cox proportional hazards model suggested that patients younger than 60 years and patients who received a D90 higher than 110 Gy may survive for a longer period.

Conclusions

I seed implantation provides a safe and effective method to relieve pain, control local tumor growth and, to some extent, prolong the survival of patients with stage II and III pancreatic disease, without additional complications. Age and accumulated dose may be factors predictive of a favorable outcome for patients with unresectable pancreatic carcinoma treated with 125I seeds. These findings need to be validated by conducting further studies with larger cohorts.
Appendix
Available only for authorised users
Literature
1.
go back to reference Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 2012, 62: 10-29. 10.3322/caac.20138.CrossRef Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 2012, 62: 10-29. 10.3322/caac.20138.CrossRef
2.
go back to reference Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN, Dooley WC, Coleman J, Pitt HA: Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg. 1995, 221: 721-731. 10.1097/00000658-199506000-00011.CrossRef Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN, Dooley WC, Coleman J, Pitt HA: Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg. 1995, 221: 721-731. 10.1097/00000658-199506000-00011.CrossRef
3.
go back to reference Wang C, Wu H, Xiong J, Zhou F, Tao J, Liu T, Zhao G, Gou S: Pancreaticoduodenectomy with vascular resection for local advanced pancreatic head cancer: a single center retrospective study. J Gastrointest Surg. 2008, 12: 2183-2190. 10.1007/s11605-008-0621-9.CrossRef Wang C, Wu H, Xiong J, Zhou F, Tao J, Liu T, Zhao G, Gou S: Pancreaticoduodenectomy with vascular resection for local advanced pancreatic head cancer: a single center retrospective study. J Gastrointest Surg. 2008, 12: 2183-2190. 10.1007/s11605-008-0621-9.CrossRef
5.
go back to reference Furuse J, Ogino T, Ryu M, Kinoshita T, Konishi M, Kawano N, Ishikura S, Shimizu W, Sekiguchi R, Moriyama N, Iwasaki M, Yoshino M: Intraoperative and conformal external-beam radiation therapy in patients with locally advanced pancreatic carcinoma, results from a feasibility phase II study. Hepatogastroenterology. 2000, 47: 1142-1146. Furuse J, Ogino T, Ryu M, Kinoshita T, Konishi M, Kawano N, Ishikura S, Shimizu W, Sekiguchi R, Moriyama N, Iwasaki M, Yoshino M: Intraoperative and conformal external-beam radiation therapy in patients with locally advanced pancreatic carcinoma, results from a feasibility phase II study. Hepatogastroenterology. 2000, 47: 1142-1146.
6.
go back to reference Furuse J, Kinoshita T, Kawashima M, Ishii H, Nagase M, Konishi M, Nakagohri T, Inoue K, Ogino T, Ikeda H, Maru Y, Yoshino M: Intraoperative and conformal external-beam radiation therapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic carcinoma. Cancer. 2003, 97: 1346-1352. 10.1002/cncr.11165.CrossRef Furuse J, Kinoshita T, Kawashima M, Ishii H, Nagase M, Konishi M, Nakagohri T, Inoue K, Ogino T, Ikeda H, Maru Y, Yoshino M: Intraoperative and conformal external-beam radiation therapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic carcinoma. Cancer. 2003, 97: 1346-1352. 10.1002/cncr.11165.CrossRef
7.
go back to reference Wang JJ, Jiang YL, Li JN, Tian SQ, Ran WQ, Xiu D: Intraoperative ultrasound-guided iodine-125 seed implantation for unresectable pancreatic carcinoma. J Exp Clin Cancer Res. 2009, 28: 1-6. 10.1186/1756-9966-28-1.CrossRef Wang JJ, Jiang YL, Li JN, Tian SQ, Ran WQ, Xiu D: Intraoperative ultrasound-guided iodine-125 seed implantation for unresectable pancreatic carcinoma. J Exp Clin Cancer Res. 2009, 28: 1-6. 10.1186/1756-9966-28-1.CrossRef
8.
go back to reference Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer. 1981, 47: 207-214. 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6.CrossRef Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer. 1981, 47: 207-214. 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6.CrossRef
9.
go back to reference International Association for the Study of Pain, Subcommittee on Taxonomy: Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Pain. 1986, 3 (Suppl): 221-226. International Association for the Study of Pain, Subcommittee on Taxonomy: Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Pain. 1986, 3 (Suppl): 221-226.
10.
go back to reference Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, Vilardell F, Wang Z, Keller JW, Banerjee P, Herman JM, Cameron JL, Yeo CJ, Halushka MK, Eshleman JR, Raben M, Klein AP, Hruban RH, Hidalgo M, Laheru D: DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009, 27: 1806-1813. 10.1200/JCO.2008.17.7188.CrossRef Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, Vilardell F, Wang Z, Keller JW, Banerjee P, Herman JM, Cameron JL, Yeo CJ, Halushka MK, Eshleman JR, Raben M, Klein AP, Hruban RH, Hidalgo M, Laheru D: DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009, 27: 1806-1813. 10.1200/JCO.2008.17.7188.CrossRef
11.
go back to reference Gillen S, Schuster T, Friess H, Kleeff J: Palliative resections versus palliative bypass procedures in pancreatic cancer–a systematic review. Am J Surg. 2012, 203: 496-502. 10.1016/j.amjsurg.2011.05.004.CrossRef Gillen S, Schuster T, Friess H, Kleeff J: Palliative resections versus palliative bypass procedures in pancreatic cancer–a systematic review. Am J Surg. 2012, 203: 496-502. 10.1016/j.amjsurg.2011.05.004.CrossRef
12.
go back to reference Gutt R, Liauw SL, Weichselbaum RR: The role of radiotherapy in locally advanced pancreatic carcinoma. Nat Rev Gastroenterol Hepatol. 2010, 7: 437-447. 10.1038/nrgastro.2010.98.CrossRef Gutt R, Liauw SL, Weichselbaum RR: The role of radiotherapy in locally advanced pancreatic carcinoma. Nat Rev Gastroenterol Hepatol. 2010, 7: 437-447. 10.1038/nrgastro.2010.98.CrossRef
13.
go back to reference Gastrointestinal Tumor Study Group: Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst. 1988, 80: 751-755.CrossRef Gastrointestinal Tumor Study Group: Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst. 1988, 80: 751-755.CrossRef
14.
go back to reference Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouche O, Bosset J, Aparicio T, Mineur L, Azzedine A, Hammel P, Butel J, Stremsdoerfer N, Maingon P, Bedenne L: Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study. Ann Oncol. 2008, 19: 1592-1599. 10.1093/annonc/mdn281.CrossRef Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouche O, Bosset J, Aparicio T, Mineur L, Azzedine A, Hammel P, Butel J, Stremsdoerfer N, Maingon P, Bedenne L: Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study. Ann Oncol. 2008, 19: 1592-1599. 10.1093/annonc/mdn281.CrossRef
15.
go back to reference Loehrer PJ, Powell ME, Cardenes HR, Wagner L, Brell JM, Ramanathan RK, Crane CH: A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201 [abstract]. J Clin Oncol. 2008, 26: a4506- Loehrer PJ, Powell ME, Cardenes HR, Wagner L, Brell JM, Ramanathan RK, Crane CH: A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201 [abstract]. J Clin Oncol. 2008, 26: a4506-
16.
go back to reference Ioka T, Nakamura S, Nishiyama K: A randomized phase II study of gemcitabine 1000 mg/msq and concurrent radiotherapy comparing gemcitabine alone for unresectable locally advanced pancreatic adenocarcinoma [abstract]. Int J Radiat Oncol Biol Phys. 2010, 78: S102-CrossRef Ioka T, Nakamura S, Nishiyama K: A randomized phase II study of gemcitabine 1000 mg/msq and concurrent radiotherapy comparing gemcitabine alone for unresectable locally advanced pancreatic adenocarcinoma [abstract]. Int J Radiat Oncol Biol Phys. 2010, 78: S102-CrossRef
17.
go back to reference Hoyer M, Roed H, Sengelov L, Traberg A, Ohlhuis L, Pedersen J, Nellemann H, Berthelsen A, Eberholst F, Engelholm SA, von der Maase H: Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol. 2005, 76: 48-53. 10.1016/j.radonc.2004.12.022.CrossRef Hoyer M, Roed H, Sengelov L, Traberg A, Ohlhuis L, Pedersen J, Nellemann H, Berthelsen A, Eberholst F, Engelholm SA, von der Maase H: Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol. 2005, 76: 48-53. 10.1016/j.radonc.2004.12.022.CrossRef
18.
go back to reference Mahadevan A, Jain S, Goldstein M, Miksad R, Pleskow D, Sawhney M, Brennan D, Callery M, Vollmer C: Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2010, 78: 735-742. 10.1016/j.ijrobp.2009.08.046.CrossRef Mahadevan A, Jain S, Goldstein M, Miksad R, Pleskow D, Sawhney M, Brennan D, Callery M, Vollmer C: Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2010, 78: 735-742. 10.1016/j.ijrobp.2009.08.046.CrossRef
19.
go back to reference Schellenberg D, Kim J, Christman-Skieller C, Chun CL, Columbo LA, Ford JM, Fisher GA, Kunz PL, Van Dam J, Quon A, Desser TS, Norton J, Hsu A, Maxim PG, Xing L, Goodman KA, Chang DT, Koong AC: Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2011, 81: 181-188. 10.1016/j.ijrobp.2010.05.006.CrossRef Schellenberg D, Kim J, Christman-Skieller C, Chun CL, Columbo LA, Ford JM, Fisher GA, Kunz PL, Van Dam J, Quon A, Desser TS, Norton J, Hsu A, Maxim PG, Xing L, Goodman KA, Chang DT, Koong AC: Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2011, 81: 181-188. 10.1016/j.ijrobp.2010.05.006.CrossRef
20.
go back to reference Polistina F, Costantin G, Casamassima F, Francescon P, Guglielmi R, Panizzoni G, Febbraro A, Ambrosino G: Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. Ann Surg Oncol. 2010, 17: 2092-2101. 10.1245/s10434-010-1019-y.CrossRef Polistina F, Costantin G, Casamassima F, Francescon P, Guglielmi R, Panizzoni G, Febbraro A, Ambrosino G: Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. Ann Surg Oncol. 2010, 17: 2092-2101. 10.1245/s10434-010-1019-y.CrossRef
21.
go back to reference Nagai S, Fujii T, Kodera Y, Kanda M, Sahin TT, Kanzaki A, Yamada S, Sugimoto H, Nomoto S, Takeda S, Morita S, Nakao A: Prognostic implications of intraoperative radiotherapy for unresectable pancreatic cancer. Pancreatology. 2011, 11: 68-75. 10.1159/000324682.CrossRef Nagai S, Fujii T, Kodera Y, Kanda M, Sahin TT, Kanzaki A, Yamada S, Sugimoto H, Nomoto S, Takeda S, Morita S, Nakao A: Prognostic implications of intraoperative radiotherapy for unresectable pancreatic cancer. Pancreatology. 2011, 11: 68-75. 10.1159/000324682.CrossRef
22.
go back to reference Ogawa K, Karasawa K, Ito Y, Ogawa Y, Jingu K, Onishi H, Aoki S, Wada H, Kokubo M, Ogo E, Etoh H, Kazumoto T, Takayama M, Nemoto K, Nishimura Y: Intraoperative radiotherapy for unresectable pancreatic cancer: a multi-institutional retrospective analysis of 144 patients. Int J Radiat Oncol Biol Phys. 2011, 80: 111-118. 10.1016/j.ijrobp.2010.01.065.CrossRef Ogawa K, Karasawa K, Ito Y, Ogawa Y, Jingu K, Onishi H, Aoki S, Wada H, Kokubo M, Ogo E, Etoh H, Kazumoto T, Takayama M, Nemoto K, Nishimura Y: Intraoperative radiotherapy for unresectable pancreatic cancer: a multi-institutional retrospective analysis of 144 patients. Int J Radiat Oncol Biol Phys. 2011, 80: 111-118. 10.1016/j.ijrobp.2010.01.065.CrossRef
23.
go back to reference Pfreundner L, Baier K, Schwab F, Willner J, Bratengeier K, Flentje M, Feustel H, Fuchs KH: 3D-Ct-planned interstitial HDR brachytherapy + percutaneous irradiation and chemotherapy in inoperable pancreatic carcinoma. Methods and clinical outcome. Strahlenther Onkol. 1998, 174: 133-141. 10.1007/BF03038496.CrossRef Pfreundner L, Baier K, Schwab F, Willner J, Bratengeier K, Flentje M, Feustel H, Fuchs KH: 3D-Ct-planned interstitial HDR brachytherapy + percutaneous irradiation and chemotherapy in inoperable pancreatic carcinoma. Methods and clinical outcome. Strahlenther Onkol. 1998, 174: 133-141. 10.1007/BF03038496.CrossRef
24.
go back to reference Wang J, Wang J, Liao A, Zhuang H, Zhao Y: The direct biologic effects of radioactive 125I seeds on pancreatic cancer cells PANC-1, at continuous low-dose rates. Cancer Biother Radiopharm. 2009, 24: 409-416. 10.1089/cbr.2008.0563.CrossRef Wang J, Wang J, Liao A, Zhuang H, Zhao Y: The direct biologic effects of radioactive 125I seeds on pancreatic cancer cells PANC-1, at continuous low-dose rates. Cancer Biother Radiopharm. 2009, 24: 409-416. 10.1089/cbr.2008.0563.CrossRef
25.
go back to reference Ma J, Jin Z, Si P, Liu Y, Lu Z, Wu H, Pan X, Wang L, Gong Y, Gao J, Li Z: Continuous and low-energy 125I seed irradiation changes DNA methyltransferases expression patterns and inhibits pancreatic cancer tumor growth. J Exp Clin Cancer Res. 2011, 30: 35-46. 10.1186/1756-9966-30-35.CrossRef Ma J, Jin Z, Si P, Liu Y, Lu Z, Wu H, Pan X, Wang L, Gong Y, Gao J, Li Z: Continuous and low-energy 125I seed irradiation changes DNA methyltransferases expression patterns and inhibits pancreatic cancer tumor growth. J Exp Clin Cancer Res. 2011, 30: 35-46. 10.1186/1756-9966-30-35.CrossRef
26.
go back to reference Gao J, Wang L, Xu J, Zheng J, Man X, Wu H, Jin J, Wang K, Xiao H, Li S, Li Z: Aberrant DNA methyltransferase expression in pancreatic ductal adenocarcinoma development and progression. J Exp Clin Cancer Res. 2013, 32: 86-95. 10.1186/1756-9966-32-86.CrossRef Gao J, Wang L, Xu J, Zheng J, Man X, Wu H, Jin J, Wang K, Xiao H, Li S, Li Z: Aberrant DNA methyltransferase expression in pancreatic ductal adenocarcinoma development and progression. J Exp Clin Cancer Res. 2013, 32: 86-95. 10.1186/1756-9966-32-86.CrossRef
27.
go back to reference Ma Z, Yang Y, Zou L, Luo K: 125I seed irradiation induces up-regulation of the genes associated with apoptosis and cell cycle arrest and inhibits growth of gastric cancer xenografts. J Exp Clin Cancer Res. 2012, 31: 61-70. 10.1186/1756-9966-31-61.CrossRef Ma Z, Yang Y, Zou L, Luo K: 125I seed irradiation induces up-regulation of the genes associated with apoptosis and cell cycle arrest and inhibits growth of gastric cancer xenografts. J Exp Clin Cancer Res. 2012, 31: 61-70. 10.1186/1756-9966-31-61.CrossRef
28.
go back to reference Zhuang H, Wang J, Liao A, Wang J, Zhao Y: The biological effect of 125I seed continuous low dose rate irradiation in CL187 cells. J Exp Clin Cancer Res. 2009, 28: 12-10. 10.1186/1756-9966-28-12.CrossRef Zhuang H, Wang J, Liao A, Wang J, Zhao Y: The biological effect of 125I seed continuous low dose rate irradiation in CL187 cells. J Exp Clin Cancer Res. 2009, 28: 12-10. 10.1186/1756-9966-28-12.CrossRef
29.
go back to reference Shipley WU, Nardi GL, Cohen AM, Ling CC: Iodine-125 implant and external beam irradiation in patients with localized pancreatic carcinoma: a comparative study to surgical resection. Cancer. 1980, 45: 709-714. 10.1002/1097-0142(19800215)45:4<709::AID-CNCR2820450416>3.0.CO;2-5.CrossRef Shipley WU, Nardi GL, Cohen AM, Ling CC: Iodine-125 implant and external beam irradiation in patients with localized pancreatic carcinoma: a comparative study to surgical resection. Cancer. 1980, 45: 709-714. 10.1002/1097-0142(19800215)45:4<709::AID-CNCR2820450416>3.0.CO;2-5.CrossRef
30.
go back to reference Handley WS: Pancreatic cancer and its treatment by implanted radium. Ann Surg. 1934, 100: 215-223. 10.1097/00000658-193407000-00021.CrossRef Handley WS: Pancreatic cancer and its treatment by implanted radium. Ann Surg. 1934, 100: 215-223. 10.1097/00000658-193407000-00021.CrossRef
31.
go back to reference Hilaris BS, Roussis K: Cancer of the Pancreas. Handbook of Radiotherapy Brachytherapy. Edited by: Hilaris BS. 1975, American National Cancer Institute, Acton Mass Publishing Sciences Group, 251-262. Hilaris BS, Roussis K: Cancer of the Pancreas. Handbook of Radiotherapy Brachytherapy. Edited by: Hilaris BS. 1975, American National Cancer Institute, Acton Mass Publishing Sciences Group, 251-262.
32.
go back to reference Morrow M, Hilaris B, Brennan MF: Comparison of conventional surgical resection, radioactive implantation, and bypass procedures for exocrine carcinoma of the pancreas 1975–1980. Ann Surg. 1984, 199: 1-5. 10.1097/00000658-198401000-00001.CrossRef Morrow M, Hilaris B, Brennan MF: Comparison of conventional surgical resection, radioactive implantation, and bypass procedures for exocrine carcinoma of the pancreas 1975–1980. Ann Surg. 1984, 199: 1-5. 10.1097/00000658-198401000-00001.CrossRef
33.
go back to reference Syed AM, Puthawala AA, Neblett DL: Interstitial iodine-125 implant in the management of unresectable pancreatic carcinoma. Cancer. 1983, 52: 808-813. 10.1002/1097-0142(19830901)52:5<808::AID-CNCR2820520510>3.0.CO;2-U.CrossRef Syed AM, Puthawala AA, Neblett DL: Interstitial iodine-125 implant in the management of unresectable pancreatic carcinoma. Cancer. 1983, 52: 808-813. 10.1002/1097-0142(19830901)52:5<808::AID-CNCR2820520510>3.0.CO;2-U.CrossRef
34.
go back to reference Peretz T, Nori D, Hilaris B, Manolatos S, Linares L, Harrison L, Anderson LL, Fuks Z, Brennan MF: Treatment of primary unresectable carcinoma of the pancreas with I-125 implantation. Int J Radiat Oncol Biol Phys. 1989, 17: 931-935. 10.1016/0360-3016(89)90138-7.CrossRef Peretz T, Nori D, Hilaris B, Manolatos S, Linares L, Harrison L, Anderson LL, Fuks Z, Brennan MF: Treatment of primary unresectable carcinoma of the pancreas with I-125 implantation. Int J Radiat Oncol Biol Phys. 1989, 17: 931-935. 10.1016/0360-3016(89)90138-7.CrossRef
35.
go back to reference Ishii H, Okada S, Tokuuye K, Nose H, Okusaka T, Yoshimori M, Nagahama H, Sumi M, Kagami Y, Ikeda H: Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer. 1997, 79: 1516-1520. 10.1002/(SICI)1097-0142(19970415)79:8<1516::AID-CNCR11>3.0.CO;2-0.CrossRef Ishii H, Okada S, Tokuuye K, Nose H, Okusaka T, Yoshimori M, Nagahama H, Sumi M, Kagami Y, Ikeda H: Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer. 1997, 79: 1516-1520. 10.1002/(SICI)1097-0142(19970415)79:8<1516::AID-CNCR11>3.0.CO;2-0.CrossRef
36.
go back to reference Andre T, Balosso J, Louvet C, Hannoun L, Houry S, Huguier M, Colonna M, Lotz JP, De Gramont A, Bellaïche A, Parc R, Touboul E, Izrael V: Combined radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) as palliative treatment for localized unresectable or adjuvant treatment for resected pancreatic adenocarcinoma: Results of a feasibility study. Int J Radiat Oncol Biol Phys. 2000, 46: 903-911. 10.1016/S0360-3016(99)00478-2.CrossRef Andre T, Balosso J, Louvet C, Hannoun L, Houry S, Huguier M, Colonna M, Lotz JP, De Gramont A, Bellaïche A, Parc R, Touboul E, Izrael V: Combined radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) as palliative treatment for localized unresectable or adjuvant treatment for resected pancreatic adenocarcinoma: Results of a feasibility study. Int J Radiat Oncol Biol Phys. 2000, 46: 903-911. 10.1016/S0360-3016(99)00478-2.CrossRef
37.
go back to reference Kornek GV, Schratter-Sehn A, Marczell A, Depisch D, Karner J, Krauss G, Haider K, Kwasny W, Locker G, Scheithauer W: Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin. Br J Cancer. 2000, 82: 98-103.CrossRef Kornek GV, Schratter-Sehn A, Marczell A, Depisch D, Karner J, Krauss G, Haider K, Kwasny W, Locker G, Scheithauer W: Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin. Br J Cancer. 2000, 82: 98-103.CrossRef
38.
go back to reference Boz G, De Paoli A, Innocente R, Rossi C, Tosolini G, Pederzoli P, Talamini R, Trovò MG: Radiotherapy and continuous infusion 5-fluorouracil in patients with nonresectable pancreatic carcinoma. Int J Radiat Oncol Biol Phys. 2001, 51: 736-740. 10.1016/S0360-3016(01)01708-4.CrossRef Boz G, De Paoli A, Innocente R, Rossi C, Tosolini G, Pederzoli P, Talamini R, Trovò MG: Radiotherapy and continuous infusion 5-fluorouracil in patients with nonresectable pancreatic carcinoma. Int J Radiat Oncol Biol Phys. 2001, 51: 736-740. 10.1016/S0360-3016(01)01708-4.CrossRef
Metadata
Title
The investigation of 125I seed implantation as a salvage modality for unresectable pancreatic carcinoma
Authors
Hao Wang
Junjie Wang
Yuliang Jiang
Jinna Li
Suqing Tian
Weiqiang Ran
Dianrong Xiu
Yang Gao
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2013
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-32-106

Other articles of this Issue 1/2013

Journal of Experimental & Clinical Cancer Research 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine